Curasept Aphthae Rapid: mouthwashes, gels, sprays for canker sores | Curasept

Curasept Afterapid

Discover the products

This page is intended for international users only, to access Italian content, please switch to the Italian website on the upper right corner of this web page.

MOUTH ULCERS:
A TROUBLESOME ISSUE

Aphthous ulcers are the most common lesions of the oral mucosa, and in 80% of cases the first aphthous ulcer appears before the age of 30.
The prevalence of this problem can affect up to 60%* of the population. It is estimated that in one-fifth of cases, episodes are frequent and repeated over the years

*S Jurge 1, R Kuffer, C Scully, S R Porter Mucosal Disease Series. Number VI. Recurrent Aphthous Stomatitis Review Oral Dis , 12 (1), 1-21 Jan 2006

PREDISPOSING FACTORS

Nutritional deficiencies

Systemic diseases

Psychological conditions

Mucosal injuries

Genetic predisposition

Allergies and intolerances

THE SYMPTOMS

Spontaneous pain and burning at phonation.
Swelling and pain in nearby lymph nodes.
Increased salivation.
Difficulty and pain in chewing with possible loss of appetite.
Difficulty and pain with oral hygiene maneuvers.
Diagnosis is mainly based on clinical appearance and medical history.

THE AFTERAPID FORMULATION

It's a comprehensive and innovative formulation based on the emulsion of MUCOADESIVE POLYMERS ENRICHED WITH ACTIVE PARTICLES that protect the wound, provide relief and accelerate healing.

icona DNA/RNA, presente nella formulazione di Curasept Afterapid poiché accelera la guarigione delle afte

DNA/RNA

STIMULATES BIOLOGICAL MECHANISMS OF TISSUE REPAIR

icona Biomoist acido ialuronico, presente nella formulazione di Curasept Afterapid poiché protegge e dona sollievo dalle afte

BIOMOIST® HYALURONIC ACID

FILM-FORMING AND MOISTURIZING POWER

icona tea tree oil e olio di manuka, presente nella formulazione di Curasept Afterapid per l'attività antibatterica e antifungina che proteggono e accelerano la guarigione delle afte

TEA TREE OIL AND MANUKA OIL

ANTIBACTERIAL AND ANTIFUNGAL ACTIVITY

icona acido glicirretico, presente nella formulazione di Curasept Afterapid per l'attività antinfiammatoria che offre sollievo e accelera la guarigione delle afte

18ß GLYCIRRETIC ACID

ANTI-INFLAMMATORY FUNCTION

icona ruscogenina, usata nei prodotti della linea Curasept afterapid per la sua attività astringente, che protegge, offre sollievo e accelera la guarigione delle afte

RUSCOGENIN

ASTRINGENT ACTIVITY

icona allantoina, usata nei prodotti della linea Curasept afterapid perché accelera la guarigione dalle afte

ALLANTOIN

CELL PROLIFERATION

QUICK RELIEF, QUICK RECOVERY.

Forms a lipid-protective film on the wound.

DISCOVER THE FULL RANGE

mouthwash 125ml and pack Curasept Afterapid

CURASEPT AFTERAPID MOUTHWASH

gel and pack Curasept Afterapid

CURASEPT AFTERAPID PROTECTIVE GEL

spray e pack Curasept AfteRapid

CURASEPT AFTERAPID SPRAY

DISCOVER ALL THE BRANDS

Accessibility Adjustments

Powered by OneTap

Select your accessibility profile

Vision Impaired Mode

Enhances website's visuals

Seizure Safe Profile

Clear flashes & reduces color

ADHD Friendly Mode

Focused browsing, distraction-free

Blindness Mode

Reduces distractions, improves focus

Epilepsy Safe Mode

Dims colors and stops blinking

Content

Colors

Orientation

Quality Policy

The Quality for CURASEPT S.p.A. is an essential condition to put itself successfully on the market, considering its characteristics and evolution.

The development of the Company and its profit are insured by the continuous search for quality towards excellence through the continuous improvement of its processes and the search for partners with quality systems adapted to our standards.

The Company aims to increase the customer satisfaction through the application of its Quality Management System, including the processes to improve the system and to ensure the compliance with the customer and applicable regulatory requirements.

For this purpose, the Company performs specific risks and opportunities assessment activities, connected to the context, stakeholders and related objectives, in order to identify the areas of system improvements and to define the appropriate actions for the risk control and mitigation and strengthening of its Quality System.

The starting point for the implementation of this policy is the pursuit of the following objectives:

Define and implement a Quality Management System according to 9001:2015+A1:2024 e UNI CEI EN ISO 13485:2021 regulation, as Manufacturer of Medical Devices;
Define and implement a system of procedures and operating instructions in harmony with the Directive 93/42/CEE, the Regulation (UE) 2017/745 and the Regulation (UE) 2023/607 for the applicable parts and subsequent changes and integrations, which satisfy the essential requirements set out in Annex I;
Define and implement a system of procedures in harmony with the Directive 2010/84, the Regulation 1235/2010, the Implementation Regulation n. 520/2012 and in accordance with the objectives of “module I – “Good Vigilance Practices” (GVP);
Establish and formalize the business organizational structure with the subdivision into areas of competences;
Clarify roles and responsibilities of business functions;
Define strategies and objectives and assign human and material resources for their achievement;
Define accurately business processes and related performance factors;
Ensure compliance with qualitative, quantitative and temporal requirements;
Constantly monitor the level of adequacy of the system with reference to regulations and laws;
Promote initiatives in order to improve the process of motivational and professional growth of human resources, considered as critical resources for future business developments;
Ensure the commitment to the satisfaction of requirements and the maintenance of effectiveness of the Quality Management System.

These objectives can be realized thanks to the involvement of the whole Company personnel.

In particular, the Managers of each Function provide their contribution so that the suggested improvements can be proposed to the General Direction, so that the Quality Policy can be a priority element in the choice of business qualitative and organizational strategies.

The involvement of the whole personnel in the improvement of internal and external processes should be aimed at reducing non-compliance and internal and external costs of non-quality; for this reason all employees should feel themselves committed in pursuing this policy.

Training courses, for all business levels, are promoted and planned by the General Direction in order to keep the personnel constantly up to date on the improvements performed for the processes.

The Quality Manual, which is distributed via the SistemaQualità to all process managers and the General Director, should represent a work tool for all Managers and their personnel for the implementation of the Quality Policy.

April 2025

General Direction